New drug shows promise against multiple advanced cancers
NCT ID NCT04892342
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 33 times
Summary
This study tested a new drug called ESG401 in 156 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study included many cancer types, such as breast, lung, and colorectal cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS, COLORECTAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.